Jefferies Financial Group set a $150.00 price objective on Amedisys (NASDAQ:AMED) in a report published on Monday, Stock Target Advisor reports. The brokerage currently has a buy rating on the health services provider’s stock.
A number of other research analysts have also commented on AMED. Raymond James reaffirmed a buy rating and set a $21.00 price target on shares of Colfax in a research report on Thursday, May 2nd. BidaskClub raised Zai Lab from a sell rating to a hold rating in a research report on Wednesday, June 5th. ValuEngine raised Zumiez from a sell rating to a hold rating in a research report on Saturday, June 22nd. Finally, Barclays set a €77.00 ($89.53) price target on HeidelbergCement and gave the company a buy rating in a research report on Thursday, March 21st. Seven equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. The stock has a consensus rating of Buy and an average target price of $131.43.
AMED opened at $123.00 on Monday. The firm’s 50 day simple moving average is $117.47. The company has a market cap of $3.87 billion, a price-to-earnings ratio of 30.43, a price-to-earnings-growth ratio of 1.50 and a beta of 1.34. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.91 and a quick ratio of 0.91. Amedisys has a one year low of $92.08 and a one year high of $140.91.
In other news, Director Bruce D. Perkins bought 2,500 shares of the firm’s stock in a transaction dated Wednesday, May 15th. The stock was purchased at an average price of $111.84 per share, with a total value of $279,600.00. Following the transaction, the director now owns 22,088 shares of the company’s stock, valued at $2,470,321.92. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider David L. Kemmerly sold 5,000 shares of the stock in a transaction that occurred on Monday, May 20th. The stock was sold at an average price of $109.96, for a total value of $549,800.00. The disclosure for this sale can be found here. Insiders sold a total of 45,028 shares of company stock valued at $5,210,707 in the last three months. Corporate insiders own 2.90% of the company’s stock.
Large investors have recently made changes to their positions in the company. Vanguard Group Inc boosted its holdings in shares of Amedisys by 14.3% in the third quarter. Vanguard Group Inc now owns 3,326,180 shares of the health services provider’s stock worth $415,640,000 after buying an additional 415,060 shares during the period. LPL Financial LLC acquired a new position in shares of Amedisys in the fourth quarter worth about $300,000. PNC Financial Services Group Inc. boosted its holdings in shares of Amedisys by 8.9% in the fourth quarter. PNC Financial Services Group Inc. now owns 3,923 shares of the health services provider’s stock worth $459,000 after buying an additional 322 shares during the period. New York State Common Retirement Fund boosted its holdings in shares of Amedisys by 11.7% in the fourth quarter. New York State Common Retirement Fund now owns 47,155 shares of the health services provider’s stock worth $5,522,000 after buying an additional 4,955 shares during the period. Finally, Private Advisor Group LLC acquired a new position in shares of Amedisys in the fourth quarter worth about $297,000. 86.30% of the stock is owned by hedge funds and other institutional investors.
Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, social workers, and aides for its patients to complete their important personal tasks.
Featured Article: What is a Tariff?
Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.